Salinero-Fort Miguel A, San Andrés-Rebollo Francisco J, de Burgos-Lunar Carmen, Gómez-Campelo Paloma, Chico-Moraleja Rosa M, López de Andrés Ana, Jiménez-García Rodrigo
Gerencia de Atención Primaria. Gerencia Adjunta de Planificación y Calidad, Servicio Madrileño de Salud. Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain.
Centro de Salud Las Calesas, Servicio Madrileño de Salud, Madrid, Spain.
PLoS One. 2015 Apr 9;10(4):e0122030. doi: 10.1371/journal.pone.0122030. eCollection 2015.
To evaluate the incidence rate of Chronic Kidney Disease (CKD) stage 3-5 (persistent decreased kidney function under 60 mL/min per 1.73 m2) among patients with type 2 diabetes over five years, to identify the risk factors associated with CKD, and develop a risk table to predict five-year CKD stage 3-5 risk stratification for clinical use.
The MADIABETES Study is a prospective cohort study of 3,443 outpatients with type 2 diabetes mellitus, sampled from 56 primary health care centers (131 general practitioners) in Madrid (Spain).
The cumulative incidence of CKD stage 3-5 at five-years was 10.23% (95% CI = 9.12-11.44) and the incidence density was 2.07 (95% CI = 1.83-2.33) cases per 1,000 patient-months or 2.48 (95% CI = 2.19-2.79) cases per 100 patient-years. The highest hazard ratio (HR) for developing CKD stage 3-5 was albuminuria ≥ 300 mg/g (HR = 4.57; 95% CI= 2.46-8.48). Furthermore, other variables with a high HR were age over 74 years (HR = 3.20; 95% CI = 2.13-4.81), a history of Hypertension (HR = 2.02; 95% CI = 1.42-2.89), Myocardial Infarction (HR= 1.72; 95% IC= 1.25-2.37), Dyslipidemia (HR = 1.68; 95% CI 1.30-2.17), duration of diabetes mellitus ≥ 10 years (HR = 1.46; 95% CI = 1.14-1.88) and Systolic Blood Pressure >149 mmHg (HR = 1.52; 95% CI = 1.02-2.24).
After a five-year follow-up, the cumulative incidence of CKD is concordant with rates described in Spain and other countries. Albuminuria ≥ 300 mg/g and age over 74 years were the risk factors more strongly associated with developing CKD (Stage 3-5). Blood Pressure, lipid and albuminuria control could reduce CKD incidence of CKD in patients with T2DM.
评估2型糖尿病患者五年内慢性肾脏病(CKD)3 - 5期(持续肾功能下降至低于60 mL/分钟/1.73平方米)的发病率,确定与CKD相关的危险因素,并制定一个风险表以预测五年内CKD 3 - 5期的风险分层供临床使用。
MADIABETES研究是一项前瞻性队列研究,对来自西班牙马德里56个初级卫生保健中心(131名全科医生)的3443例2型糖尿病门诊患者进行了抽样。
五年内CKD 3 - 5期的累积发病率为10.23%(95%可信区间 = 9.12 - 11.44),发病密度为每1000患者 - 月2.07例(95%可信区间 = 1.83 - 2.33)或每100患者 - 年2.48例(95%可信区间 = 2.19 - 2.79)。发生CKD 3 - 5期的最高风险比(HR)是蛋白尿≥300 mg/g(HR = 4.57;95%可信区间 = 2.46 - 8.48)。此外,其他高HR的变量包括74岁以上(HR = 3.20;95%可信区间 = 2.13 - 4.81)、高血压病史(HR = 2.02;95%可信区间 = 1.42 - 2.89)、心肌梗死(HR = 1.72;95%可信区间 = 1.25 - 2.37)、血脂异常(HR = 1.68;95%可信区间1.30 - 2.17)、糖尿病病程≥10年(HR = 1.46;95%可信区间 = 1.14 - 1.88)和收缩压>149 mmHg(HR = 1.52;95%可信区间 = 1.02 - 2.24)。
经过五年随访,CKD的累积发病率与西班牙和其他国家描述的发病率一致。蛋白尿≥300 mg/g和74岁以上是与发生CKD(3 - 5期)关联更强的危险因素。控制血压、血脂和蛋白尿可降低2型糖尿病患者CKD的发病率。